<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771611</url>
  </required_header>
  <id_info>
    <org_study_id>20-009705</org_study_id>
    <nct_id>NCT04771611</nct_id>
  </id_info>
  <brief_title>COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications</brief_title>
  <acronym>COVFIS-HOME</acronym>
  <official_title>COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James L. Kirkland, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the&#xD;
      reduction of complications in patients with COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether short-term treatment with Fisetin reduces the rate of death and long&#xD;
      term complications related to COVID-19 and to determine the safety of treatment with Fisetin&#xD;
      in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>Need for hospitalization and death with COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Hauler Syndrome</measure>
    <time_frame>60 days</time_frame>
    <description>Assessment for long hauler syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment drug Fisetin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>~20mg/kg /day oral for four days (days 0,1 and days 8,9)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>3,3',4',7-tetrahydroxyflavone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, at least 18 years of age, capable and willing to provide informed&#xD;
             consent;&#xD;
&#xD;
          -  Patient must have received a diagnosis of COVID-19 infection within the last 3 days;&#xD;
&#xD;
          -  Outpatient setting (not currently hospitalized);&#xD;
&#xD;
          -  Patient must possess at least one of the following high-risk criteria: 60 years or&#xD;
             more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension&#xD;
             (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma,&#xD;
             chronic obstructive pulmonary disease, or present or past smoking), known heart&#xD;
             failure, known coronary disease, fever of ≥38.4°C within the last 48 hours, dyspnea at&#xD;
             the time of presentation, the combination of high neutrophil count and low lymphocyte&#xD;
             count;&#xD;
&#xD;
          -  Female patient is either not of childbearing potential, defined as postmenopausal for&#xD;
             at least 1 year or surgically sterile, or is of childbearing potential and practicing&#xD;
             at least one method of contraception and preferably two complementary forms of&#xD;
             contraception including a barrier method (e.g. male or female condoms, spermicides,&#xD;
             sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study&#xD;
             and for 30 days after study completion;&#xD;
&#xD;
          -  Patient or their caregiver must be able and willing to comply with the requirements of&#xD;
             this study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient currently hospitalized or under immediate consideration for hospitalization;&#xD;
&#xD;
          -  Patient currently in shock or with hemodynamic instability;&#xD;
&#xD;
          -  Patient with severe hepatic disease (as per clinical judgement) and liver enzymes &gt;10x&#xD;
             the upper limit of normal;&#xD;
&#xD;
          -  Female patient who is pregnant, breast-feeding, or is considering becoming pregnant&#xD;
             during the study or for 1 day after the last dose of study medication;&#xD;
&#xD;
          -  Patient currently taking Sirolimus, Tacrolimus, or other mTOR inhibitors for other&#xD;
             indications (mainly chronic indications represented by organ transplantation or&#xD;
             autoimmune diseases);&#xD;
&#xD;
          -  On Warfarin therapy;&#xD;
&#xD;
          -  Patient with a history of an allergic reaction or significant sensitivity to Fisetin;&#xD;
&#xD;
          -  Patient undergoing chemotherapy for cancer;&#xD;
&#xD;
          -  Patient is considered by the investigator, for any reason, to be an unsuitable study&#xD;
             candidate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avni Y. Joshi, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara K Evans</last_name>
    <phone>507-284-1004</phone>
    <email>evans.tamara@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tamara K Evans</last_name>
      <phone>507-284-1004</phone>
      <email>evans.tamara@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Avni Joshi, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland, MD, PhD</investigator_full_name>
    <investigator_title>Co-Principal Investigator and Regulatory Sponsor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

